Precision Medicine Scientists


Scientific breakthroughs are the hallmark of precision medicine

The future of precision medicine depends on continued emphasis on scientific research.

Our mission is to understand how an individual’s genetic profile affects the drug response. This will provide immediate benefit to patients and enable development of next generation therapies tailored to account for genetic variation. We strive to continue being pioneers in genomic research with a persistent drive to translate scientific breakthroughs into clinical progress.

The RPRD team has a long history of pioneering translational research, including major contributions to the knowledge base of PGx and establishing its clinical utility.

Our leading-edge diagnostic testing has brought a once theoretical concept of preemptive PGx into practical clinical use and benefited thousands of patients already.

The potential for precision medicine to improve patient care is vast. Tremendous strides have been made toward promising clinical applications for PGx. Yet many actionable genetic variants and gene-drug associations need to be uncovered and validated by well-designed and robust studies. RPRD is committed to implementing the latest PGx technologies and remaining at the forefront of the science.

Scientific PGx Collaboration

We encourage like-minded researchers and clinicians who foresee the power and promise of precision medicine to contact us for potential research collaboration. 

Research at RPRD

Our decades-long experience in genetics research has produced many articles in peer-reviewed scientific journals, expanding the knowledge base of PGx and its clinical applications.

Clinical Trials and Drug Discovery

Pharmacogenetics testing is an increasingly important tool to mitigate risks for clinical trials, interpretation of clinical data and retrospective studies.

Improve Patient Outcomes

Through our continued research in advanced PGx technologies and solutions, we help clinicians practice personalized medicine to achieve better outcomes for their patients.